PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
4DMedical Limited (ASX:4DX) Partners with Olympus to Launch SeleCT™ Screening Campaign
4DMedical Limited (ASX:4DX) partners with Olympus to deploy AI-powered SeleCT™ Screening, enhancing COPD diagnosis and treatment.
Siren Gold Limited (ASX:SNG) Announces High-Grade Antimony-Gold Update at Langdons
Siren Gold Limited (ASX:SNG) reports significant gold and antimony grades from its Langdons project, highlighting exploration progress and next steps.
Radiopharm Theranostics (ASX:RAD) Receives FDA Fast Track for RAD101
Radiopharm Theranostics (ASX:RAD) secures FDA Fast Track for RAD101, advancing its Phase 2 trial in brain metastases imaging.
Fletcher Building Limited (ASX:FBU) Receives Inquiries Amid Strategic Review
Fletcher Building (ASX:FBU) receives inquiries following strategic review, with further details to be disclosed at Investor Day.
Finbar Group Limited (ASX:FRI) Announces Early Appointment of Ronald Chan as CEO
Finbar Group Limited (ASX:FRI) appoints Ronald Chan as CEO ahead of schedule, emphasizing leadership stability and future growth.
Zip Co Limited (ASX:ZIP) Upgrades FY25 Guidance Amid Strong May Performance
Zip Co Limited (ASX:ZIP) upgrades FY25 guidance to $160m cash EBTDA, citing strong May performance and US TTV growth above 40%.
Zenith Minerals Limited (ASX:ZNC) Secures Strategic Acquisition to Expand Dulcie Gold Project
Zenith Minerals (ASX:ZNC) acquires exclusive subsurface rights to expand its Dulcie Gold Project, enhancing exploration and reducing operational risks.
Centrex Limited (ASX:CXM) Reconvenes Second Meeting of Creditors
Centrex Limited (ASX:CXM) reconvenes its second creditors meeting, proposing a DOCA by PRL Global Limited.
Syntara Limited (ASX:SNT) Receives FDA Fast Track Designation for SNT-5505
Syntara Limited (ASX:SNT) secures FDA Fast Track for its myelofibrosis treatment SNT-5505, accelerating its development towards becoming a new standard of care.